Wang Li-juan, Zhou Hui, Lu Huai-wu, Li Jing, Lin Zhong-qiu
Department of Gynecological Oncology, Sun Yat-Sen University, Guangzhou, China.
Zhonghua Yi Xue Za Zhi. 2011 Nov 8;91(41):2927-30.
To evaluate whether high sensitivity C-reactive protein (hs-CRP) is a predictive factor in the patients with endometrial cancer.
The investigators retrospectively analyzed the clinical records of 110 patient with endometrial carcinoma treated at our institution for their initial serum hs-CRP level at pre-operation. Pearson's chi-square was used to evaluate the association of the level of hs-CRP with variables associated with a poor prognosis. COX proportional hazard model was employed to perform univariate and multivariate analyses.
The median serum level of hs-CRP in the patients with endometrial cancer was 5.58 mg/L (range: 0.02 - 140.54 mg/L). The serum level of hs-CRP was significantly associated with advanced tumor stage (P < 0.01), lymph node involvement (P < 0.05) and patient age (P < 0.05). Tumor stage, lymph node involvement, histological grade, post-operative adjuvant therapy and the serum level of hs-CRP were correlated with the overall and disease-free survivals. Tumor stage and the serum level of hs-CRP were independent factors. The rank correlation analysis showed that there was a positive correlation between the serum levels of hs-CRP and CA125 (P < 0.01).
The serum level of hs-CRP may serve as a prognostic parameter in patients with endometrial cancer. Further studies are warranted to validate its value.
评估高敏C反应蛋白（hs-CRP）是否为子宫内膜癌患者的一个预测因素。
研究者回顾性分析了在本机构接受治疗的110例子宫内膜癌患者术前的初始血清hs-CRP水平临床记录。采用Pearson卡方检验评估hs-CRP水平与预后不良相关变量之间的关联。采用COX比例风险模型进行单因素和多因素分析。
子宫内膜癌患者血清hs-CRP的中位数水平为5.58mg/L（范围：0.02 - 140.54mg/L）。hs-CRP血清水平与肿瘤晚期（P < 0.01）、淋巴结受累（P < 0.05）及患者年龄（P < 0.05）显著相关。肿瘤分期、淋巴结受累、组织学分级、术后辅助治疗及hs-CRP血清水平与总生存期和无病生存期相关。肿瘤分期和hs-CRP血清水平是独立因素。秩相关分析显示hs-CRP血清水平与CA125之间存在正相关（P < 0.01）。
hs-CRP血清水平可能作为子宫内膜癌患者的一个预后参数。有必要进一步研究以验证其价值。
